

About this seminar

The pharma industry is under constant pressure to discover new and safer drugs to treat diseases with a high medical need. In the past decade, pipelines have started to dry up and the approval of new chemical entities has decreased steadily.

This conference highlights some of the current changes in the field of drug discovery, which could turn around this decreasing trend. In general, innovation is the cornerstone for all these changes. New models of academic drug discovery and collaborations between pharma companies, biotechs and universities are being investigated and implemented in order to increase innovation. New target classes and phenotypic drug discovery come again to the foreground to identify new chemical entities with innovative mechanisms of action. Finally, progress in technologies which can improve the drug discovery process and increase the success rates are highlighted.

International experts from pharma, biotech and academia will discuss the above topics followed by an open panel discussion at the end of this 1-day conference.

Programme

09h00 **Registration participants**

09h45 **Introduction**

Prof. Koenraad Debackere (Managing Director, K.U.Leuven R&D)

Part A: Changes in collaboration and business models

10h05 **The Centre for Drug Design and Discovery**

Dr. Patrick Chaltin, Managing Director CD3

10h25 **Business perspective**

Case to be announced

10h50 **What do large pharma look for in academic collaborations?**

Dr. David Reynolds, Executive Director New Opportunities Unit, Pfizer

11h20 **Q & A**

11h30 **Coffee / tea break**

Part B: Hot targets

11h55 **Targeting protein-protein interactions**

Prof. Zeger Debyser, Head of Division Molecular Medicine, K.U.Leuven - Coordinator IWT-SBO CellCoVir

12h15 **Epigenetic drug discovery**

Speaker to be announced

12h35 **The revival of phenotypic screening: rethinking mechanisms of drug discovery**

Dr. David C. Swinney, CEO iRND3, Institute for Rare and Neglected Diseases Drug Discovery

13h00 **Q & A**

13h15 **Sandwich lunch**

Part C: Innovations in supportive technologies

14h20 **Target discovery: chemical proteomics and cofradic in target discovery**

Mathias Laga, Post-Doc Medical Protein Research Lab, VIB/UGent

14h40 **Innovative biophysics for fragment-based drug discovery**

Dr. Gregg Siegal, CSO ZoBio - Protein Chemistry, University of Leiden

15h05 **Predicting toxicity: Zebrafish as an in vivo model for predicting drug-induced multi-organ toxicity**

Dr. Natalie Mesens, Drug safety group, Janssen Pharmaceutical Companies of Johnson & Johnson and Dr. Camila Esguerra, Laboratory of Pharmaceutical Biology, K.U.Leuven

15h25 **Q & A**

15h50 **Coffee / tea break**

Part D: Meeting the challenges

16h15 **Keynote presentation: Your strategy and your organisation in constant evolution, an international view**

Dr. Malcolm Skingle, Director, Academic Liaison, Medicines Discovery and Development, GSK

16h45 **Panel discussion "Meeting the challenges"**

17h15 **Closing remarks**

17h30 **Drinks**

Who should attend?

- Industrial and academic researchers
- Biotechnology Sector
- Pharmaceutical industry
- Public Health Policy
- Business development or project managers
- Technology transfer professionals
- Funding agencies
- Proof-of-concept or translational centres
- Executives and members of the investment community interested in drug research

In cooperation with

This seminar is organized in collaboration with the **Centre for Drug Design and Discovery (CD3)** and **K.U.Leuven Research & Development (LRD)**.

The Centre for Drug Design and Discovery (CD3) is a technology transfer and value creation platform in the field of small molecule drug discovery and target validation. CD3 focuses on the discovery of innovative small molecule drugs by complementing the high level and ground-breaking biology present at universities and small (spin-off) companies. By providing professional expertise and financial means, CD3 stimulates the discovery and development of innovative drugs for multiple diseases and ensures that the enormous pool of knowledge, innovation and technologies of universities and spin-off companies is used adequately. Newly discovered potential drugs can then be further developed by the existing pharma or biotech industry or can form the basis of new spin-off companies. In this way, the Centre intends to bridge the gap between academic biomedical research and the needs of the pharma and biotech industry. The Katholieke Universiteit Leuven and the European Investment Fund (EIF) have entered a partnership agreement in 2006 to create CD3.

LRD was established in 1972 as one of the first technology transfer offices in Europe and has a long tradition in collaboration with industry, patenting, licensing and spin-off creation. LRD is dedicated to building bridges between science and industry and to transferring knowledge and technologies to the marketplace. The LRD-team guides both researchers and companies through all aspects of the technology transfer process.

Registration and payment before November 15, 2011

We advise you to register via our website at <http://www.leuveninc.com/page/12/Events/>

or fax this document to +32 (0)16 40 81 47
or +32 (0)16 29 83 19

I would like to register for this seminar:

- € 160 : Academic researcher
- € 260 : Leuven.Inc member
- € 360 : Other participant

<p>Participation in our activities at 50% discount via KMO-portefeuille Pijler Opleiding: Leuven.Inc Approval number DV.O106761 More info: www.kmo-portefeuille.be</p>	
--	---

First name:

Last name:

Function:

Company:

VAT Number:

Company address:

.....

.....

Company telephone:

Company fax:

E-mail:

Invoice address – please indicate if different from participant (address and contact person)
.....

.....

Signature

Date:

.....

Information and Registration

Date: Monday November 21, 2011 (09h00-18h00)
Location: Brabantal, Leuven
Route description: www.brabantal.be

Participation fee: (exclusive of 21% VAT)

- € 160 : Academic researcher
- € 260 : Leuven.Inc member
- € 360 : Other participant

To register for this seminar, go to our website at <http://www.leuveninc.com/page/12/Events/>

Or fax your registration to +32 (0)16 40 81 47
or +32 (0)16 29 83 19

Fee is payable after receipt of invoice from Leuven.Inc. The fee includes coffee, sandwiches, documentation and drinks.

Cancellation after subscription is not possible, but replacement by a colleague is allowed. After registration you will receive confirmation and a route description.

For more info, please contact the seminar coordinator:
Nicole De Smyter – Leuven.Inc
Tel. +32 (0)16 40 11 90 – Fax +32 (0)16 40 81 47
E-mail: info@leuveninc.com

Registration and payment before November 15, 2011

Seminar Coordinator



Leuven.Inc (Leuven Innovation Networking Circle) wants to build a network and communication platform between and for knowledge centers, high-tech entrepreneurs, established enterprises and their socio-economic partners. Leuven.Inc also wants to participate in the international network of the knowledge community. For more info on events and membership, please visit www.leuveninc.com or mail to info@leuveninc.com



How to increase innovation and success in drug discovery?

Monday November 21, 2011

Brabantal, Leuven (Belgium)

